Zydus Cadila gets USFDA nod to mineral supplement Potassium Chloride ER Tablets

Published On 2020-09-18 08:37 GMT   |   Update On 2020-09-18 08:37 GMT
Advertisement

Ahmedabad: Drugmaker, Zydus Cadila recently announced that the company has received final approval from the US Food & Drug Administration( USFDA) to market Potassium Chloride Extended-Release Tablets, a mineral supplement used to treat or prevent low amounts of potassium in the blood. The product in the strengths of 10 mEq (750 mg) and 20 mEq (1500 mg) will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 301 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Cadila cancer treatment injection Doxorubicin Hydrochloride Liposome gets USFDA okay

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Read also: COVID-19 Vaccine: Zydus Cadila, Bharat Biotech in Phase II trial



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News